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Lung Cancer—Elapsed Time from Suspicious Radiograph to
Treatment: How Fast is Fast Enough?
Kenneth G. Torrington, MD
Starting in the mid 1990s, the Department of Veterans Affairs (VA) implemented aseries of process improvements that catapulted its health care system into elite
company in U.S. medicine.1,2 Focusing on health maintenance and disease prevention and
working in conjunction with Department of Defense medical leaders, the VA developed
a series of evidence-based, Clinical Practice Guidelines (CPGs) and introduced them into
Primary Care Clinics and to a lesser extent the in-patient environment throughout its
national system.3 One component of the VAs remarkable success as a health system has
been regionalizing health care into 21 Veterans Integrated Service Networks (VISNs),
whose compliance with VA CPGs has been monitored and tracked by the VA Central
Office. Leaders and clinicians from compliant VISNs have served as proponents and
trainers for less successful VISNs. Thus, VA transformation resulted from the combina-
tion of strong central oversight and regional autonomy.
In the current issue of JTO, Powell and his colleagues describe an initial assessment
of how long it takes veterans with suspicious lung nodules or masses to receive definitive
treatment. Their study data are representative of national veterans’ care, since 133 of 139
VA medical centers participated. At first glance, the study’s primary end point, that a
median of 71 days elapse between finding a suspicious pulmonary lesion and delivering
definitive treatment, seems excessive. However, it is important to analyze individual
factors contributing to the elapsed time to determine whether treatment should be
considered delayed or appropriate.
Data collected in the study are subject to multiple limitations. The start time for each
patient’s study entry began when either a chest radiograph or chest computed tomography
(CT) scan revealed a lesion suspicious for malignancy. However, these imaging proce-
dures are not equivalent. Chest radiographs are rapid, safe, and widely available, so it is
likely that at least some abnormal chest radiographs were ordered as screening procedures.
CT scans, on the other hand, are not ordered routinely. Thus, patients diagnosed by CT
scan would much more likely have been symptomatic and their diagnostic evaluations
would have been shortened. Another study weakness is that the authors did not describe
radiographic characteristics of the lesions. Simply reporting lesion size would have
stratified the risk that an individual lesion was malignant.4 An additional study weakness
is that over 10% of VA medical centers are located in geographic regions of the United
States in which a large numbers of pulmonary nodules are caused by endemic mycotic
infections. Appropriate standard of care at these centers may require several months
follow-up of pulmonary lesions likely to be granulomatous, before initiating diagnostic
evaluation for malignancy.
Most veterans, including those reported in this study, are complicated medical
patients, who tend to be elderly and have multiple comorbidities. The cigarette smoking
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which predisposed them to the development of lung cancer
has typically caused chronic obstructive pulmonary disease,
atherosclerotic heart disease, and other tobacco-associated
diseases. The VA patient population is additionally charac-
terized by significant prevalence of mental illness and home-
lessness, two factors which greatly complicate treatment
planning and implementation.
The National Cancer Institute statement about anxiety
disorders in cancer patients’ reports that up to 44% of patients
with a suspected cancer diagnosis develop some anxiety and
23% significant anxiety during cancer screening, diagnostic
testing or recurrence.5 In the typical patient, identification of
a lesion suspicious for malignancy provokes a sense of
urgency to begin treatment. Yet Powell et al.’s study of VA
patients reported that staff at 44 of the 133 VA sites (33.1%)
identified that patient barriers (patient noncompliance, delay
in reporting symptoms and physical distance from the site) as
contributors to evaluation delays. The delayed patient re-
sponse to potentially life-threatening illness described at
one third of VA medical centers indicates that at least
some VA patients respond less than urgently to the suspi-
cion of malignancy.
Before selecting the most appropriate therapeutic
course, patients with suspicious pulmonary nodules must
undergo a series of complex diagnostic evaluations designed
to determine the operability and clinical staging of the lesion.
These include additional imaging studies such as CT scans,
positron emission tomography-CT scans and occasionally
nuclear medicine scans, fiberoptic bronchoscopy with bron-
choscopic or transthoracic tissue sampling, physiologic test-
ing of pulmonary function, and overall health assessment.
The authors seem perplexed that patients presenting
with advanced stage bronchogenic carcinoma were diagnosed
and treated more rapidly than stage I patients. In a resource-
constrained system like the VA which focuses on health
maintenance, it is understandable that patients presenting
with symptoms such as hemoptysis, dyspnea or pain, or
symptomatic distant metastases would be prioritized to more
expeditious evaluations than those with asymptomatic pul-
monary nodules. In addition, the diagnostic evaluation for
stage IIIB and IV disease patients is shortened, because they
need only a diagnosis of malignancy, before being referred
for palliative interventions.
Despite recent increases in congressional support to
$90.0B in FY 08,6 the VA remains chronically underfunded.
The huge influx of veterans from the wars in Iraq and
Afghanistan has strained resources. Therefore, it comes as no
surprise that 40.6% of reporting VA medical centers identi-
fied problems with resource adequacy, such as no access or
insufficient access to advanced imaging procedures, lack of
specialty services, and inadequate staffing.
The VA and the authors of this study should be com-
mended both for their interest in assessing the timeliness of
veterans’ access to definitive lung cancer treatment and for
their willingness to publicize this information. The study
authors noted that leaders and clinicians at “over two thirds of
participating facilities expressed concerns that arose as a
result of their chart reviews and nearly as many indicated that
they were considering specific changes or improvement ac-
tivities.” Combining these efforts with possible system-wide
changes implemented by the VA Central Office has the
potential to accelerate diagnostic evaluations for veterans
with a variety of suspected malignancies. For an organization
with over 263,000 employees which provides care for 5.5
million veterans,6 the VA has proven itself remarkably nim-
ble at implementing change. After collection and review of
additional data from this and other studies, I suspect the VA
will prove itself capable of shortening evaluation intervals for
suspected cancer patients.
In the interim, the VA, and indeed U.S. and global
health systems, will continue to grapple with the epidemic of
bronchogenic carcinoma, a disease which represents a classic
failure of disease prevention. One can hope that continued
adherence to the smoking cessation CPG, the third of 27
CPGs developed by the VA,3 will gradually reduce the
number of veterans needing treatment for this typically lethal
malignancy.
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